Synthesis of a thyroxine derivative for conjugation with malate dehydrogenase by Shi, Wen
Lehigh University
Lehigh Preserve
Theses and Dissertations
1994
Synthesis of a thyroxine derivative for conjugation
with malate dehydrogenase
Wen Shi
Lehigh University
Follow this and additional works at: http://preserve.lehigh.edu/etd
This Thesis is brought to you for free and open access by Lehigh Preserve. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Shi, Wen, "Synthesis of a thyroxine derivative for conjugation with malate dehydrogenase" (1994). Theses and Dissertations. Paper 317.
--~-~---1
AUTHOR:
Shi, Wen
.TITLE:
Synthesis of a Thyroxine
Derivative for Conjugation
with Malate
Dehydrogenase
DATE: January 15,1995
:--.-',- -"".: • '. _ -- .~ _ - ,. ~~ .',' _f. -.. _.-
- ~._--~." __ " -:0.. - -~~, ..~,,-p r-..< -,.
. --..-._. - - , -.-- -.. -.. '.- ... " . ---
SYNTHESIS OF A THYROXINE DERIVATIVE
FOR
CONJUGATION WITH MALATE DEHYDROGENASE
by .
WEN SRI
A Thesis
Presented to the Graduate and Research Committee
of Lehigh University
in Candidacy for the Degree of
Master of Science
in
Department of Chemistry
LRWGB UNIVERSITY
. December 1, 1994

ACKNOWLEDGEMENTS
The author wishes to extend her deepest appreciation to Dr. Keith 1. Schray, her
advisor, for his invaluable time, professional advice, and financial support during her
graduate study at Lehigh University.
The author also thanks Mr. Sheel Ahuja at LABORATORY SERVICES, INC. for
his helpful suggestions in the past year.
A special thanks to my husband, Charlie C. Yang, for his understanding and
support in pursuing my education.
..
•.. _-- -- -- '. - -.-,
:. ~- ..-...,_.".. ~- ..-...,""_:.._.;.:.:~~;!"...::::._~~~~~:..;;.~...,.",..~ .. -- -- . - ----- ._.._~
111
----_ ... -.-
TABLE OF CONTENTS
Page
TITLE PAGE .
CERTIFICATE OF APPROVAL , ii
ACK.NOWLEDGEMENTS , iii
TABLE OF CONTENTS :........................ iv
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. VI
LIST OF FIGURES ;'. . . . . . . . . . . .. vii
ABSTRACT. . .. .. .. .. .. 1
RATIONALE 2
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 3
1. Background Information on Thyroxine . . . . . . . . . . . . . . . . . . . . . . .. 3
2. Classification oflmmunoassay .... --;--;-. . . . . . . . . . . . . . . . . . . . . .. 4
3. Types of Enzyme-Immunoassay. . . . . . . . . . . . . . . . . . . . . . . . . . .. .. 5
3. Background information about MDH . . . . . . . . . . . . . . . . . . . . . . . .. 7
THEORY ; , 10
1. Assay Method Design 10
1.1 Principle of the Assay 10
1.2 Test of Enzyme Activity . . . . . . . . . . . . . . . . . . . . . . . . . . .. 11
2. Conjugation De~ign 12
2.1 Methyl thyroxine hydrochloride . . . . . . . . . . . . . . . . . . . . . .. 12
2.2 N-Methyl, N-carboxymethylglycyl Thyroxine Methyl Ester
(Compound I) , 13
2.3 T4-MEMIDA N-hydroxysuccinirnide Ester (Compound IT) 14
2.4 T4-derivative <lI1d MDH Conjugation 15
EXPERIMENTAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 17
. 1. Materials" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 17 ..- .-"........... .,
2. Reagents (Buffers) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . .. 18
3. Equipment 19
4. Procedure of Conjugatioii"'''~·· .. "~-: - - -:-~"--.- ·:-.--~19-·--· .'-"--" ~--'"
4. r Preparation of N~methylirriinodiacetic Acid Anhydride .'. . . . .. 19
iv
4.2 Preparation of Methyl Thyroxine Hydrochloride 20
4.3 Preparation of N-Methyl, N-carboxymethylglycyl Thyroxine
Methyl Ester. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 20
4.4 Preparation of T4-MEMIDA N-hydroxysuccinimide Ester
(Compound II) 21
4.5 Preparation of Conjugate 22
5. Procedure of Immunoassay . . . . . . . . . . . . . . . . . . . . . . . .. 22
5.1 Test the Concentration of T4-derivative in the Conjugate
Solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 22
5.2 Original Enzyme and Conjugated Enzyme Activity Assay 22
5.3 Reactivation Test of Conjugated Enzyme 23
5.4 Enzyme Immunoassay 23
RESULTS 23----------
1. Reaction Schemes 25
2. Enzyme Conjugation '. . . . . . . .. 26
3. Enzyme Activity Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 27
4. Thyroxine Enzyme Immunoassay . . . . . . . . . . . . . . . . . . . . . . . . . . .. 28
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 38
1. Enzyme Immunoassay of Thyroxine ( : . .'.. 38
2. Stability of the Conjugate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 38
3. Purification of Antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 39
4. Purification of Conjugate :........................ 39
CONCLUSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 40
REFERENCES 41
BRIEF BIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 43
--__ .- r _., ,., • _ .....
v
-------- ---------
LIST OF TABLES
~--
Page
Table 1 Comparison of RIA, ErA, and FIA . . . . . . . . . . . . . . . . . . . . . . . . . .. 6
Table 2 Molecular Properties of Malate Dehydrogenase 8
Table 3 Amino Acid Composition of the Mitochondrial Malate Dehydrogenase
from Pig Heart . . . . . . . . . . . . . . . . . . . . . . .r-. • • • • • • • • • • • • • • • •• 9
Table 4 Volume of Each Reagent in Enzyme Activity Test . . . . . . . . . . . . . .. 23
Table 5 Volume of Each Reagent in EIA Test .. . . . . . . . . . . . . . . . . . . . . .. 24
Table 6 Clinical Values of Total T4
vi
29
--~----------_._-------_ .._- . ----_._-------_..~._--
LIST OF FIGURES
Page
Fig. 1 Molecule of Thyroxine (T4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 3
Fig. 2 Principle of Competitive, Homogeneous Enzyme Assay for Thyroxine ... 11
Fig. 3 Molecular of T4-MEMIDA N-hydroxysuccinimide Ester . . . . . . . . . . . .. 12
.----.Eig.A.. EQrmati.QO of M~thyl Thyroxine Hydrochloride. . . . . . . . . . .. . . . . . . .. 13
Fig. 5 Formation of N-methyl, N-carboxymethylglycyl Thyroxine Methyl Ester
(Compound I) .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 14
Fig. 6 Formation of T4-MEMIDA N-hydroxysuccinimide Ester (Compound II) .. 15
Fig. 7 Formation of T4-derivative and MDH Conjugate 16
Fig. 8 Thin Layer Chromatography of Compound I . . . . . . . . . . . . . . . . . . . . .. 30
Fig. 9 Thin Layer Chromatography of Compound II 31
Fig. 10 Comparison of Reaction Rate
between Conjugate Enzyme and Original Enzyme. . . . . . . . . . . . . . . .. 32
Fig. 11 Inhibition of Conjugated Enzyme before and after Dialysis. . . . . . . . . .. 33
Fig. 12 RIA Response Curve for Thyroxine Derivative 34
Fig. 13 Conjugate Dissociation vs Time 35
Fig. 14 Reactivation of T4-MDH Conjugate by Adding Anti-T4 Antibody ..... 36
Fig. 15 Homogeneous Enzym~immunoassay Response Curve for Thyroxine. . .. 37
vii
ABSTRACT
. Thyroxine is a competitive inhibitor of malate dehydrogenase. For decades, studies
have been conducted to improve the inhibitory effect of the thyroxine. The objective of
this project is to synthesize a thyroxine derivative for malate dehydrogenase conjugation
that is used for a competitive homogeneous enzyme immunoassay. Malate dehydrogenase
labelled with the thyroxine derivative, a N-methyl,--N-carboxymetliylglycyl- thyroxine
methyl ester (T4-MEMIDA) N-hydroxysuccinimide ester, shows over 90% inhibition of
enzyme activity. The conjugated ~alate dehydrogenase is enzymatically inactive but
becomes active after binding with anti-thy~oxine antibodies. The thyroxine derivative
appears to inhibit the enzyme by hindering its active site, whereas the antibody reactivates j'
~
the enzyme by pulling the thyroxine away from the active site. The thyroxine conjugate
is stable at 4DC for one week without adding any preservative and stabilizer. In
competitive homogeneous enzyme immunoassay, the thyroxine from a sample competes
with the enzyme conjugate for antibody binding sites and results in reduction of the
enzyme reactivation. A set of six samples with different concentrations of thyroxine is
used to generate a standard curve. Without separation steps involved, the distinction
between free and antibody-bound labeled antigen can be made entirely based on
enzymatic activity.
RATIONALE
The interpretation of variation in T4, T3, TSH, and TBG levels is very important
in clinical practice. When the thyroxine concentration falls outside the normal range,
hyper- or hypothyroidism is suspected. Measurement of T3 uptake, TSH, or total T3 can
,
confirm the diagnosis. A multiple assay system for simultaneous detection of all these
components will reduce costs in diagnosis. However, multiple assay systems involve
separate sequential steps for each enzyme reaction. Elimination of separation steps will
bring simultaneous assays a significant advance for practical application. With the
characteristics of rapid testing and no separation step required, homogeneous enzyme-
. .
immunoassay is more favorable for multiple assay systems than others. Therefore, our
study is to synthesize the thyroxine derivative and malate dehydrogenase conjugation that
can be used for competitive homogeneous enzyme immunoassay. It is expected that
advantages of fast testing procedure, small sample vQlume, and higher precision will help
to create a simpler simultaneous detection for thyroid hormone diagnosis.
2
INTRODUCTION
1. Background Information on Thyroxine
Thyroxine, the iodinated amino acid 3,5,3' ,5' -tetraiodo-L-thyronine (T4), is
secreted by the thyroid gland along with 3,3' ,5' -triiodo-L-thyronine, (T3) (Fig. 1) [1,2].
Fig. 1 Molecule of Thyroxine (T4)
The secretion is controlled by the pituitary thyroid-stimulating hormone (TSH)
which is affected by hypothalamic thyrotropin-releasing hormone (TRH). Normally, the
increase in blood level of T4 and T3 leads to the decrease in the amount of TSH secreted,
thereby reducing the production and secretion of T4 and T3. On the other hand, the
decrease in blood level of T4 and T3 results in the opposite effect, leading to more
production and secretion of T4 and T3. In this manner, a normal balance of circulating
thyroid hormone is maintained. Upon entering into blood, T4 is strongly bound by
specific plasma proteins, especially by thyroid-binding globulin (TBG). Because of the
.
very high affinity of TBG for T4, more than 99.9% of T4 is bound and less than 0.1 %
of T4 is free. The free T4 penetrates into cells, induces stimulation of metabolism, and
controls feedback via pituitary. Although the free fractionofT4_is. influenced not only by
.-._-_... - ~-_._;- ..~., ~- ---
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the total circulating T4, but also by the amount of thyroxine-binding proteins in the blood,
measurement of total thyroxine concentration is the most common preliminary procedure
used to detect thyroid disease. When the thyroxine concentration falls outside the normal
range, hyper- or hypothyroidism is suspected. Measurement of T3 uptake, TSH, or total
T3 can confirm the diagnosis.
2. Classification of Immunoassay
Several methods in determining total T4 levels are available. Immunoassay is one
of the common diagnostic methods that is applied using an antibody/antigen reaction.
Immunoassay can be classified as radioimmunoassay (RIA), enzyme immunoassay (EIA),
and fluoroimmunoassay (PIA). Most of radioimmunoassay utilizes the competition of
labeled ligand that may be either a hapten or a macromolecular antigen (Ag*) with the
corresponding unlabeled ligand or an analyte (Ag) from a sample for a limited number
of antibody binding sites (Ab) -[4, 5, 6].
Ab + Ag* == Ab.Ag*
+
Ag
II
Ab.Ag
As shown above, the concentration of antibody binding sites available to bind the
radio-labeled ligand is inversely related to the concentration of analyte present in the
sample. Radioimmunoassay is a sensitive and specific technique and has been proved
extremely valuable in clinical chemistry. I:Iowever... this method does have several
- ---- - ,::--:- ...• '~~'~,-~--..~ ..~., -~~.-::.--;-_.-;--------
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limitations. I) Most useful radioisotopes have relatively short half-lives. 2) Potentially
hazardous levels of radioactivity are encountered during labeling procedures. 3) There are
problems with disposal and ,release of radioactivity into the environment. 4) The
requirement of a separation step during the assay is a particular disadvantage of RIA.
Therefore, a variety of non-isotopic labels has been investigated in an attempt to retain
the advantages of RIA without the association with radioisotopes. Two assay methods,
enzyme immunoassay and fluorescence immunoassay, have been developed to compete
favorably with radioimmunoassay in many areas of performance. Fluorescence
immunoassay is based on the principle that certain molecules (fluorophores) can absorb
light at one wavelength and emit light at a longer wavelength. However, the sensitivity
of fluorescence determination is low in practice because of the background 'noise'. The
noise can-be due to either light scattering or the presence of fluorophores other than the
I
label itself. Enzyme labels are currently the most widely used non-isotopic labels for the
following reasons. First of all, there is no -contact with radioactive material required.
Secondly, the activities of several enzyme labels can be easily determined with commonly
available spectrophotometer. Also, the reagents have a much longer half-life. Furthermore,
the separation step is not required in some assays.
3. Types of Enzyme-Immunoassay
Enzyme-immunoassay can be categorized as either "heterogenous" or
"homogeneous." In heterogeneous enzyme-immunoassay, the separation of free and bound
labeled molecul~.s is necessary. However, in hO,mogeneous assays, th~separation step is
5
not required. An essential difference between these two assays is that the enzyme on the
labeled antigen or antibody retains its activity in heterogeneous assay [4, 7].
(1) Competitive heterogeneous EIA for Antigen -- Labeled antigen competes with
unlabeled antigen for the binding to a limited quantity of antibody. This procedure is
Table 1
Comparison of RIA, EIA, and FIA
RIA .Hornogeh-e-ous-- -Heterogeneous--- -FIk
EIA EIA
Sensitivity Very High Low High High
Precision Good Good Good Low
Complexity Rather Simple Rather Complex
Complex Complex
Assay Time Hours Minutes ,HOIJIS __ Hours
-.
Equipment Isotope Photometer Photometer Fluorescence
Counter Microscope
Automation High Very High High Low
Potential
Reagent Low-- High High Variable
Stability
Required High Medium Medium High
Expertise
analogous to the classical radioimmunoassay and fluorescence-immunoassay. The only
major diff~rence is in the use of an enzyme rather than an isotope ?r fluorescent.dye as
the label on antigen.
(2) Sandwich EIA for Antigen -- This procedure requires the antigen to have at
6
least two binding sites. Antigen reacts with excess solid-phase antibody, and after
incubation followed by washing, the bound antigen is treated with excess labeled
antibody. After further washing the bound label is assayed, and this provides a direct
measure of the' amount of antigen present.
(3) Homogeneous EIA for Hapten -- This type of EIA does not require the
separation of free and bound label because the assay depends on inhibition or activation
of the enzyme label.
~~- ..-~_.....
3. Background information about MDH
-~--_._.._-~_._.~~~~~~~-
Malate dehydrogenase (MDH), a common enzyme in the tricarboxylic acid cycle,
is composed of two identical subunits that are held together by varying interactions [4].
These two subunits can dissociate without losing catalytic activity and reassemble in the
presence of substrate. Each subunit has a molecular weight about 35000 daltons and
contains one binding site for a c()~p.zyme. Malate dehydrogenase activity is measured with
spectrophotometer that monitors absorbance at 340 nm due to NAD reduction or NADH
oxidation. With oxaloacetate and NADH as substrates, initial reaction velocities are about
four times greater than that with malate and NAD as substrates (Table 2) [9, 10].
Malate dehydrogenase from pig heart mitochondria consists of 318 amino acids
_ ..op. eCich su~unit. Th~ amino acjd comp9sition i~~h_o\y.!1. in table 3. This enzyme c~I].!~E_~.
14 SH groups that are not involved in catalytic reaction but are required for maintaining
the three dimensional structure of the enzyme. Although the modification of many amino
,~, -
7
acids can result in enzyme· inactivation, only histidine has been clearly proved as a
catalytic active residue. Malate dehydrogenase is stable for at least.a year at 4°C in 50%
/ .
glycerol solution. Once dialyzed against phosphate buffer, it should be stored at -20°e.
Table 2
Molecular Properties of Malate Dehydrogenase
Mass ( daltons ) 70,000
Subunits 2
.Isoelectric point 6.2
Dissociation constant
NADH ( Tris buffer, pH 8.0 ) 2.16 uM
Apparent KIn
Oxaloacetate 4.5xlO-5 M <I
NADH 3.2xlO-5 M
pH optimum 7.4
Activators Phosphate, Zn2+, Malate
Inhibitors Oxaloacetate, Thyroxine, Adenine,
Phenols, and Substituted Phenols
-
.... -:":-" ~~: :'_-_.~ -::_-,
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Table 3
Amino Acid Composition of the Mitochondrial Malate Dehydrogenase from Pig Heart
Lysine 26 Histidine 5
Glutamic 25 Aspartic 25
acid acid
Threonine 21 Serine 18
Arginine 8 Proline 23
~ -
Glycine 29 Alanine 33
Cystine 7 Valine 27
Methionine 6 Isoleucine 21
Leucine 28 Tyrosine 5
,j
Phenylalanine 11 Tryptophan 0
9
THEORY
1. Assay Method Design
In a competitive, homogeneous enzyme-immunoassay, three components are
usually required [2, 4]. They are antibody~ labeled-analyte (antigen or hapten), and an
unknown amount of analyte. Upon binding to antibody, the signal arising from the
immunochemicallabel must be modified, directly or indirectly. The first and still the most
widely accepted homogeneous enzyme-immunoassay for thyroxine is the enzyme
activation immunoassay. The activity of the enzyme is modulated by the thyroxine and
anti-thyroxine antibody due to the change in the configuration of the enzyme.
1.1 Principle of the Assay
Among the various enzymes, malate dehydrogenase from pig heart is a particularly
important enzyme for thyroxine because of its ability to form an inactive hapten
conjugate. Conjugation of thyroxine derivatives to pig heart mitochondrial malate
dehydrogenase results in powerful inhibition of enzyme activity [11]. When the thyroxine-
specific antibody binds to enzyme-labeled thyroxine, the inhibition of the conjugated
enzyme is partially released. Free thyroxine in the patient's sample competes with the
enzyme-labeled thyroxine for a limited number of antibody binding sites. As a result of
blocking effects of the antibody, activation of the enzyme is reduced [12]. There is an
inverse relationship between the conjugated enzyme activity and thyroxine concentration
10
in the sample (Fig. 2). The relationship between thyroxine concentration and enzyme
activity can be developed by testing the conjugated enzyme activity in a series of known
thyroxine concentration. The concentration of T4 in a sample is calculated by comparing
the enzyme activity with the standard calibration curve [1, 13, 14].
~+ +
tC:\~~
E%~J
+
Fig. 2 Principle of Competitive, Homogeneous Enzyme Assay for Thyroxine
1.2 Test of Enzyme Activity
Malate dehydrogenase consists of two identical subunits that have one active site
on each. The reactivated enzyme converts oxaloacetate into malate employing NADH as
coenzyme. MDH catalyzes the reversible reaction [4]:
Oxaloacetate + NADH + H+ ---- Malate + NAD
Generally, the absorbance -of NADHcan bemeasured with'spectrophotometer at
340 nm. According to the reaction showing above, MDH activity can be monitored by
the change in the optical density at 340 nm per min due to disappearance of NADH. If
the final volume of the assay mixture is V ml.and the optical pathway (b) 1 em, the total
activity and specific activity of en£yme can be determined as fogows: [15]
11
Total Units L!.A umol= -.- x -....=..;..:..;;.;,.-
min 6.22 A x ml
x V ml x Dilution Factor
Specific Activity = units / mg protein
2. Conjugation Design
The labeling of ~alate dehydrogenase with thyroxine is to be carried out by the
usage of N-hydroxysuccinimide (NHS) ester of the thyroxine derivatives that leads to
coupling at the amino groups of the enzyme (Fig. 3) [2].
Since the thyroxine derivative is not cOrhmercially available, an organic synthesis
is applied to couple N-methyliminodiacetic acid and thyroxine. The method used for
production of the thyroxine derivative is similar to the peptide synthesis.
10>-10>-
0COOCH3 0 CH3 0I I; I II
HO 0 0 0 CH.1?-NH-C-CH2NHCH2C-O-~
I I H 0
Fig. 3 Molecular Structure of T4-MEMIDA N-hydroxysuccinimide Ester
2.1 Methyl thyroxine hydrochloride
This step includes activation of the amino group and protectiorfOf the carb-oxyl
group. Since thyroxine contains one amino and one carboxyl group, a cyclic dipeptide
~ may·-be formed~by 'thyroxine itself. To-avoid fo~ation of undesired compounds, the
12
carboxyl group of thyroxine must be blocked. Esterification is suitable protection for the
carboxyl group. A classical method of esterification requires dry Hel gas that is a major
disadva~tage inthe operation [16]. In thisexperiment, an improved method is applied for
" -
the preparation of the methyl ester thyroxine in which 2,2-dimethoxypropane serves as
a source of the methoxyl group, the major solvent in the reaction system, a~d a reactive
reagent for the removal of water (Fig. 4) [17, 18].
+
C~OXC~
CHSO CHS
+ HCI
Thyroxine ester hydrochloride
Fig. 4 Formation of Methyl Thyroxine Hydrochloride
2.2 N-Methyl, N-carboxymethylglycyl Thyroxine Methyl Ester (Compound I)
The formation of an amide bond is the crucial step in peptide synthesis. Although
many coupling methods have been studied and improved, most of them have undesired
side reactions. The method for peptide synthesis in this paper utilizes acid anhydride as
the reactive acylating intermediate. N-methyliminodiacetic acid anhydride is a cyclic
13
-_.. --, _._.--~~. ----- --.._..-,-- .
: •••• •r
compound, in which the anhydride group is sensitive to a nucleophilic attack. Therefore,
even traces of moisture can lead to the forming of diacid. The only by-product in this step
is hydrochloric acid that can be easily removed. There are several shortcomings for this
anhydride method, such as the water sensitivity of reagent. To avoid polymerization, the
acid anhydride reagent has to be stored under careful exclusion of moisture [17,19].
Thyroxine Ester Hydrochloride j
+
N-methyliminodiacetic Acid Anhydride
*
' 9-1 COOCHs 0 0-1-
. I T 1"6
H 0 0 0 CH -C-NH-6:""'CH-N-GH-COOH2 I .22
1 1 H
N-rnethyl, N-carboxymethylglycyl Thyroxine Methyl Ester (Compound I)
+ HCI
Fig. 5 Formation of N-methyl, N-carboxymethylglycyl Thyroxine Methyl Ester
(Compound I)
2.3 T4-MEMIDA N-hydroxysuccinimide Ester (Compound II)
This is an activation step for the T4-MEMIDA conjugation to amino groups of the
enzyme.:.~(;~t.iv~~i~~.o( th~ ~(lf~o~~l group of the thyroxine derivative can be achieved by
the conversion of the carboxyl group to the reactive ester. N-hydroxysuccinimide ester is
.1
widelyused in peptide synthesis because of its excellent stability. T4-MEMIDA N-
14
• "'!
. "
(/
hydroxysuccinimide ester is formed in presence of "coupling reage~t~:tater-soluble 1-
ethyl-3 (3'-dimethylaminopropyl) carbodiimide hydrochloride is the most successful
coupling reagent for the extremely rapid synthesis of pure ester. Since the by-product is
water soluble, it can be easily washed away with w.ater [19, 20, 21, 22],
I I cooc~ ~ C~
H*O-O-CH2-~-NH-6~Cl-\,j-CH2"OOH
I )Y H
. ---N-melhyl,f'.karboxymelhylglycyl-Thyr.oxine.MethyLEsler (Compound I)
+
I + CH3CH2"=C=N-cH"cH"CH2NICH3"HCI
EDCI
+ CH"CH;!'JHCONH(CHi:JN(Cf-I.3)i"iCI
Comopund II
Fig. 6 Formation of T4-MEMIDA N-hydroxysuccinimide Ester (ComRound II)
2.4 T4-derivative and MDH Conjugation
The T4-derivative contains a reactive NHS ester that can react under mild
conditions. Acylation of the free amino groups of MDH occurs via the active NHS ester
[2,4, 12,23]. The leaving N-hydroxysuccinimide is readily soluble in water and thus can
be easily separated from the insoluble products. InactivaVon of enzyme is induced by T4-
derivative through blocking of the histidine that hi!S been clearly proved as. a catalytic
15
active residue [24, 25]. Although other research indicates that inactivation of enzyme can
be induced by the modification of the thiol groups with iodine-containing compounds,
direct oxidation of thiol groups leads to irreversible inhibition of the enzyme [26].
I-~-'- --- --
Enzyme Conju9yliOn
/
Fig. 7 Formation of T4-derivative and MDH Conjugate
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EXPERIMENTAL
1. Materials
Materials used in this experiment were obtained from the following sources:
(1) Pig heart mitochondrial malate dehydrogenase -Calzyme Laboratories, Inc.
(2) Thyroxine - Sigma Chemical Co.
(3)'" N-riletfiYliriliiiOdiacetic.acId ..~-Aldrich·Cneiri. Co.
(4) 2,2-dimethoxypropane - Sigma Chemical Co.
(5) Dimethyl formarnide (DMF) - Fisher Scientific
(6) Dry tetrahydrofuran (THF)'- Sigma Chemical Co.
(7) N-hydroxysuccinimide (NHS) - Sigma Chemical Co.
(8) l-ethyl-3-(3' -dimethylarninopropyl) carbodiimide hydrochloride (ECDI) -
Sigma Chemical Co.
• (9)
(10)
(11)
(12)
(13)
(14)
,
HydrochloriC acid - Fisher Scientific
Diethylene glycol monoethyl ether (Carbitol) - Sigma Chemical Co.
Ethyl ether - Sigma Chemical Co.
Ethyl acetate - Sigma Chemical Co.
,f
n-Heptane - Mallinckridt Chemical Works
Triethy1ainine - Eastman Organic Chemicals
(15) Acetic anhydride - Fisher Scientific
(16) Methanol - Fisher Scientific
17
(17) 1ncstar 1251 total T4 radioimmunoassay kit
(18) Anti-T4 antibody - Fitzgerald
(19) Oxalacetic acid - Sigma Chemical Co.
(20) NADH - Sigma Chemical Co.
(21) Methylene Chloride - Fisher Scientific
(22) 8-Anilino-l-naphthalene sulfonic acid (ANS) - Sigma Chemical Co.
2. Reagents (Buffers) [27]
(1) Dialysis Buffer (1 M K2HP04, 1 mM NaN3, and 1 mM EDTA):
Dissolve 17.418 g ofK2HP04, 0.065 g of NaN3, and 0.03722 g of EDTA into 100
ml of distilled water. Store at 0°-4°C.
(2) Carbonate Buffer (50 mM NaHCO/Na2C03, 25% Carbitol, and pH 9.2):
Dissolve 0.11 g of NaHC03, 0.265 g of Na2C03, and 25 ml of carbitol into 50 ml
of distilled water, adjust the pH to 9.2, and dilute to 100 m!.
(3) Potassium Phosphate Buffer (0.1 M K2HPOiKH2P04' pH 7.5):
Dissolve 14.11 g of anhydrous K2HP04, 2.18 g of anhydrous KH2P04 in 800 m1
of distilled water, adjust pH to 7.5, dilute to 1 liter, and store cold.
(4) Substrate Solution (0.5 mM oxaloacetate and 0.2 mM NADH):
Dissolve 0.0066 g of oxaloacetic acid and 0.0156 g of NADH into 100 ml of 0.1
M potassium phosphate buffer. This reagent must be fresh made right before used.
(5) 0.1 % of BSA Solution
Dissolve 0.1 g of BSA into 100 ml of PBS buffer. Store no longer than one week.
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(6) Stock Solution
a. Enzyme stock solution: 8 mg/ml
b. Conjugate stock solution: 0.8 mg/ml
c. Anti-T4 antibody stock solution: neat serum, no preservative
(7) Other Solution (Dilution)
a. enzyme dilution:
Pipet 10 ul of 8 mg/ml enzyme stock solution into 990 ul of glycerol to
make 80 ug/ml of enzyme solution.
Pipet 10 ul of 100 times diluted enzyme solution into 990 ul of potassium
phosphate buffer (pH 7.5) to make 0.8 ug/ml enzyme solution.
b. conjugate dilution:
Dilute enzyme conjugate 1000 times to make 0.8 ug/ml solution.
c. Anli-T4 antibody dilution:
Dilute antibody 100 times with 0.1 % BSA solution.
3. Equipment
· Rotavapor R 11 0
· Perkin-Elmer Lambda 3 UVlVis Spectrophotometer
· Gamma Counter
4. Procedure of Conjugation [28]
4.1 Preparation of N-methyliminodiacetic Acid Anhydride
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I
1. Reflux 1 g of N-methyliminodiacetic acid in 5 ml of acetic anhydride until all
have been essentially dissolved (about 5 to 30 minute).
2. Remove the excess acetic anhydride and acetic acid under reduced pressure
at lOood until a nearly constant weight of residue is obtained.
4.2 Prepar(lJion of Methyl Thyroxine Hydrochloride
1. 1 mrnol of thyroxine is suspended in 10-15 rnl of 2,2-dimethoxypropane, and
-------1 ml of concentrated hydrochloriCaCiuIsaaCleCl.
2. The mixture is allowed to stand at room temperature overnight.
3. The volatile reactants are removed in rotary evaporator at a bath temperature
not exceeding 60°C.
4. The remaining product is dissolved in a minimum amount of dry methanol,
and the solution is diluted with 25 ml of dry ether.
5. Suction filter the precipitation, wash the precipition with ether until white
solid forms, and weight the product.
4.3 Preparation of N-Methyl, N-carboxymethylglycyl Thyroxine Methyl Ester
1. Dissolve 0.413 g of the methyl ester thyroxine hydrochloride under nitrogen
blanket environment into a solution that contains 4 rnl of dimethyl formamide
(DMF), 5 rnl of dry tetrahydrofuran (THF), and 130 ul of dry triethylamine.
. 2. Stir the mixture for 15 minutes, then add 1.5 rnl of N-methyliminodiacetic
~
acid anhydride in 2.5 rnl of dry THF in one addition.
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3. Volatilize the solution in a rotary evaporator to make a foamy solid.
4. Dissolve the foamy solid in 12.5 ml of THF, and extract the solution with a
combination of 15 ml of distilled water and 25 ml of ethyl acetate.
5. Separate the solution, and extract the aqueous layer three times with 12.5 ml
of ethyl acetate.
6. Combine the organic layers, and extract them once with 25 ml of saturated
NaCl.
7. Dry the organic layer with anhydrous magnesium sulfate overnight
8. Suction filter of the organic layer, and evaporate the solvent to produce a
white solid.
9. Dissolve the white solid in 15 ml of THF with 10 ml of chloroform, and heat
the solution to reflux, then add n-heptane slowly.
10. Reduce the volume of the solution until a definite cloud persisted, and allow
the solution to cool down at room temperature, followed by the cooling ir a
freezer.
4.4 Preparation of T4-MEMIDA N-hydroxysuccinimide Ester (Compound II) ~
1. Dissolve 10 mg ofT4-MEMIDA and 1.3 mg ofN-hydroxysuccinimide (NHS)
into 250 ul of dry DMF.
2. Keep the reaction mixture atO°Cunder a nitrogen blanket while stirring.
3. Add 2.3 mg of l-ethyl-3(3' -dimethylaminopropyl) carbodiimide hydrochloride
(ECDI) into the mixture, and maintain the mixture at O°C until the ECDI has
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been dissolved,
4. Allow the solution to stand at 4°C overnight.
4.5 Preparation of Conjugate
1. Pipet 100 ul of MDH stock (8.0 mg/ml) into 900 ul of ~arbonate buffer.
2. Add 250 ul of DMF to 1 ml of MDH-buffer, and stir the mixture.
3. Add 12 ul total of compound II in 3 ul 'increments (15 minutes apart) to
ensure complete reac:t10n.
4. Purify the conjugates with dialysis at 2-4°C against 1 M K2HP04 , 1 mM NaN3
and 1 mM EDTA.
5. Procedure of Immunoassay
5.1 Test the Concentration of T4-derivative in the Conjugate Solution
,
1. Pipet 10 ul of Incstar T4 standard samples and 1000 times dilution of
conjugate into antibody coated tubes.
2. Add 1 ml of tracer into the tubes, and incubate for 45 minutes at room
temperature.
3. Decant the solution, and count the tubes with gamma counter.
5.2 Original Enzyme and Conjugated Enzyme Activity Assay
1. Pipet 10 ul of 0.8 ug/ml of initial enzyme solution and enzyme conjugate
solution into indiv'idual test tubes.
'",
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2. Add 2 ml of substrate into each tube, and measure the absorbance for 4
minutes.
3. Plot the figure of absorbance changes vs time, and calculate the specific
activity.
5.3 Reactivation Test of Conjugated Enzyme
1. Pipet 10 ul of 0.8 ug/ml of conjugated enzyme into series of test tubes.
2. Add different volume of anti-T4 antibodies (Fitzgerald serum fraction, diluted
100 fold) into the test tubes (Table 3).
3. Add 2 ml of substrate into these tubes, and measure the absorbance for 8
minutes.
Table 4
Volume of Each Reagent in Enzyme Activity Test
Tube # Antibody ( ul ) PBS ( ul ) Substrate (ml)
1 0 200 2
2 30 170 2
3 50 150 2
4 100 100 2
5 200 0 2
5.4 Enzyme Immunoassay
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1. Pipet 10 ul of different concentration of standard T4 sera into test tubes.
2. Add 100 ul of ANS into the tubes, and incubate the mixture for 10 minutes.
3. Add 10 ul of T4 enzyme conjugate and 100 ul of anti-T4 antibody into these
test tubes.
4. Add 2 ml of substrate into these tubes, and measure the absorbance for 8
minutes (Table 4).
5. Calculate the enzyme activity change in different T4 concentration.
~--_._~----------- -----
Table 5
Volume of Each Reagent in ErA Test
--
- ------ ---------1
Tube # STD (ul) Cone. (ug/dl) Conj. (ul) ANS (ul) Ab (ul) Subs. (ul)
1 10 a 10 100 100 2
2 10 1 10 100 100 2
3 10 4 10 100 100 2
4 10 8 10 100 100 2
5 10 12 10 100 100 2
6 10 20 10 100 100 2
••...•-, .-- .. ,-_",::,"--. :-.::...-_ - - c"
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RESULTS
1. Reaction Schemes
Thyroxine I
- IStep 1 ( 2,2-Dimethoxypropane
. I CH:P0CH3 + CH:pH
·luThYroxine_ester hy:drochloride---I
I.----HC-I-I.(
N-methyliminodiacetic acid
anhydride
Step 2
T4-MEMIDA (Compound I)
Step 3
N-hydroxysuccinimide
(
+
EDCI
T4-MEMIDA N-hydroxysuccinimide Ester (Compound II) I
Step 4 .--~ I Malate Dehydrogenase I
I. T4-MEMIDA N-hydroxysuccinimide Ester Enzyme Conjugate
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2. Enzyme Conjugation
The thyroxine ester hydrochloride was made according to step 1. The volatile
reactants and by-products were evaporated in the rotary evaporator at a bath temperature
not exceeding 60°C. Recrystallization from methanol-ether generated a white crystalline
ester hydrochloride. This was a single cOI?pound by TLC analysis as shown in Fig. 8.
Yields of the thyroxine ester hydrochloride was 97% in this procedure.
Theoretically, only compound I is generated in step 2. In practice, however, a
couple of side reactions might occur. Because N-methyliminodiacetic acid anhydride was
prepared through refluxing the N-methyliminodiacetic acid in excess acetic anhydride, the
product was slightly more than the expected amount. Distillation under vacuum can
remove most acetic anhydride at 110°C and acetic acid at 90°C. In this step, a dark brown
oil was obtained, which might be anhydride mixture instead of pure N-
methyliminodiacetic acid anhydride. After the coupling of methyl ester thyroxine
hydrochloride with anhydride mixture, a thick brown oil was obtained. When the thick
brown oil was extracted by the combination of distilled water and ethyl acetate, and by
the subsequent aqueous saturated sodium chloride, a yellow oil was obtained. Most
undesired by-products were removed within aqueous phase [29]. Since the prcfdlict is an
oily material, the percentage of yield can not be calculated at this step. Thin-layer
chromatography (TLC) was performed in triethylamine/methanol/methylene chloride
(0.2: 1: 10, v/v) solvent to test the product purity. As indicated in Fig. 8, some un-reacted
N-methylimino'diacetic acid anhydride and methyl thyroxine hydrochloride remained,ill
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the oil.
In step 3, both N-hydroxysuccinimide and ECDI are water soluble and cao be
removed by the washing with water. Therefore, the product of compound II is quite pure.
Thin~layer chromatography was also performed on the solution with n-hexane/methylene
chloride (l :5, v/v) to test the purity of compound II (Fig. 9).
In step 4, 12 ul of compound II was added to-malate dehydrogenase solution to
inactivate the enzyme completely. In order to remove the un-reacted T4-derivatives from
the conjugated solution, dialysis was performed overnight against 1 M K2HP04, 1 mM
NaN3, and 1 mM EDTA at 2-4°C. When the. concentration of T4-derivative on both sides
of the membrane reached an equilibrium, the purification stopped.
3. Enzyme Activity Test
Reaction of malate deliydrogenase with compound II caused strong inhibition of
enzyme activity. Before the dialysis, the conjugated enzyme' was 97.4% inhibited. After
dialysis, the enzyme activity was 81.3% inhibited (Figs. 10, 11). In order to test the
concentration of the T4-derivative in solution, a regular radioimmunoassay was conducted
by the using of Incstai' mull T4 kit. The concentration of T4-derivative in solution was
determined by interpolation from the T4 standard curve in the form of count per minute
(CPM) vs concentration (ug/dL) (Fig. 12) [30]. The concentration of T4 derivatives was
32,000 ug/dl and 18,300 ug/dl before and after the dialysis respectively. Apparently,
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excess thyroxine derivatives were removed through the dialysis, and the binding of
thyroxine with enzyme reached a new equilibrium. In this experiment, we assumed that
the protein concentrations remain unchanged before and after conjugation. Based on the
calculation result, an average of 1.73 thyroxine derivative had bound to each enzyme.
The thyroxine conjugate was stable at 4DC for one week and degraded rapidly on
second week. On day eight, there was about 47.2% of inhibition left. And, on day forty,
therewasbhly-lT5%-ofinlfioitionleft (Fig~-13). It seemed that about -17:5%-orenzyme---~-~­
inactivation was irreversible.
Addition of the anti-thyroxine antibody to the conjugate led to the restoring of
enzyme activity (Fig. 14). The optimal amount of anti-thyroxine antibodies added was 100
ul of 100 fold dilution. Without addition of anti-thyroxine antibody, the conjugated
enzyme had 18.7% of initial enzyme activity. With addition of 100 ul of 100 fold dilution
antibody, the conjugated enzyme had 59.3% of initial enzyme activity. With addition of
200 ul of 100 dilution antibody, the conjugated enzyme had 69.1 % of initial enzyme
activity. Further addition of the antibody slightly increased conjugated enzyme activity.
4. Thyroxine Enzyme Immunoassay
Sera from clinically diagnosed hypothyroid (n=57) and hyperthyroid patients
(n=34) have been evaluated by Becton Dickinson (Table 5) [31]. Therefore, a
concentration range between a ug/dL and 20 ug/dL was chosen to build up a standard
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curve (Fig. 15). A concentration of 0 ug/dL, 1 ug/dL,4 ug/dL, 8 ug/dL, 12ug/dL, and 20
ug/dL of thyroxine in standard solution competes with enzyme labeled thyroxine
derivative for limited antibody binding sites (l00 ul of 100 fold diluted serum). If we
defined that the conjugated enzyme activity is 100% when the thyroxine concentration is
oug/dL in solution, the calculated result indicated that the conjugated enzyme activity is
71.8% when the thyroxine concentration is 20 ug/dL in solution. Each thyroxine
concentration between 0 ug/dL - 20 ug/dL corresponded to one activity data.
Table 6
Clinical Values of Total T4
Population Mean Range
Normal 8.33 ug/dL 5·- 12 ug/dL
~
Hypothyroid 2.21 ug/dL 0-4.8 ug/dL
Hyperthyroid 15.6 ug/dL 11.7 - 19.5 ug/dL
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DISCUSSION
1. Enzyme Immunoassay of Thyroxine
1- ----'F~o"'r'__'o"__v:_::e"_r__"'te=n~Y_ear:&.the rnajOLSignificance-of-a-hoIDQgengous-enzyme-immunoassay
for serum thyroxine has been the fact that it can be adapted to an automated biochemical
profiling instrument. At present, the major advantage for us to study thyroxine
homogeneous enzyme immunoassay is that it can be applied in the simultaneous enzyme
immunoassay for thyroid function tests. In RIA, the simultaneous assay can not be
~
approached to test more than two analytes because of the requirement of the separation
steps and the limited source of the radioisotope. On the other hand, simultaneous testing
three or four analytes is possible in EIA by labeling these analytes with different enzymes
and testing enzyme activities in different wavelengths. Since the enzyme activity of
thyroxine-MDH conjugate can be detected in ultraviolet wavelength, there is no color
interfere with other visible wavelength absorbance. Therefore, it is significant to study the
thyroxine-MDH conjugate for developing simultaneous assay.
2. Stability of the Conjugate
One of the advantages of EIA is the high stability of reagents. In our experiment,
the enzyme conjugate is less stablf<Jhan expe,cted. Since some of stabilizers may interfere
with the malate dehydrogenase activity, the synthesized enzyme conjugate remains
unstable. In order to store the conjugate for longer time, an effective approach is to
38
lyophilize the conjugate, store it in a solid form, and dissolve the required amount right
before use.
In this experiment, anti-thyroxine antibody sera were used to reactivate enzyme.
Many proteins in the serum might interfere with enzyme activity detection. Besides, the
unpurified antibody might respond to the conjugate slowly. Therefore, for better assay
performance, purification of antibodies is suggested through precipitation with 50%
saturated ammonium sulfate and DEAE-cellulose chromatography~
4. Purification of Conjugate
In order to remove excess compound II, dialysis has been conducted. During a 12
hour dialysis against 1 M phosphate buffer, the enzyme inhibition losses 16.1%.
Therefore, a better purification method for conj~gate needs to be investigated. Moreover,
-"-be~~~;~"th;'" imp~~lty-'~f'the"N::-metllyniriin6diacetiC"acid'aIlhydtitle'interferes"'withothe--"
purity of the followed products, the preparation of the N-methyliminodiacetic acid
anhydride must be further improved in such experiments.
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CONCLUSION
eonjugated-malate-dehydrogenase-with-theJhymxine_d_eri~atiye, a T4-MJj~rp_~_
---
N-hydroxysuccinimide ester, leads to over 90% inhibition of initial enzyme activity.
Addition of anti-thyroxine antibody reverses the inhibition in different degrees. Before the
addition of anti-thyroxine antibody, the conjugated enzyme has 18.7% of initial enzyme
activity. After the addition of 100 ul of 100 fold dilution antibody, the conjugated enzyme
has 59.3% of initial enzyme activity. The conjugated enzyme activity has been restored
40.7%. This volume of anti-thyroxine antibody is used for the competitive, homogeneous
enzyme immunoassay in which separation steps are no longer required. A conjugated
enzyme activity in the assay corresponds to a concentration between 0 ug/dL and 20
ug/dL. The whole procedure can be done in about 20 minutes which is three times shorter
than other procedures. The possibility of environ'!pental hazards is eliminated by the
replacement of radioisotope with enzyme label.
The project has completed the most essential step in the multiple enzyme assay
system. Further studies are needed to identify the effective combination of different
enzymes in the simultaneous T4, T3, T3U and TSH testing system.
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